- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02736305
Use of Regorafenib in Recurrent Epithelial Ovarian Cancer
An Open-Label, Single-Arm Phase 2 Clinical Trial Of Regorafenib in Patients With Multiply Recurrent Epithelial Ovarian Cancer
Studieöversikt
Detaljerad beskrivning
STUDY OBJECTIVES
The objective of this study is to evaluate the efficacy and safety of regorafenib at a dose of 120mg daily for 21 days out of every 28 day cycle in Asian females with multiply recurrent EOC.
Primary Endpoint:
Investigator assessed progression free survival (PFS)
Secondary Endpoints:
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
-
Singapore, Singapore, 169610
- National Cancer Centre Singapore
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Signed informed consent obtained before any study specific procedures. Subjects must be able to understand and willing to sign a written informed consent.
- Patients with histologically and/or cytologically confirmed epithelial ovarian carcinoma (serous, clear cell, endometrioid, mucinous, mixed, carcinosarcoma and others), fallopian tube and primary peritoneal carcinoma.
- Progressive disease following 2 or more prior cytotoxic chemotherapy. Patients may have received prior treatment with bevacizumab.
- Age ≥ 21 years old
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Life expectancy greater than 3 months
- Measurable disease by RECIST 1.1 OR non measurable but evaluable disease such as ascites and pleural effusions attributable to disease or radiologic abnormalities that did not meet RECIST criteria AND a pre-treatment serum Ca-125 level greater than or equal to 2 times the upper limit of normal on 2 occasions at least 1 week apart OR pre treatment Ca-125 level greater or equal to 2 times the upper limit of normal on 2 occasions at least 1 week apart and non evaluable, non measurable disease.
- Adequate bone marrow function as shown by: absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelet count ≥ 100 x 109/L and haemoglobin (Hb) > 9 g/dl. Blood transfusion to meet the inclusion criteria will not be allowed.
- Adequate liver function as assess by: total bilirubin ≤ 1.5 x upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN or ≤ 5.0 x ULN if liver metastases are present.
- Adequate renal function as assessed by serum creatinine ≤ 1.5 x ULN and glomerular filtration rate (GFR) ≥ 30 ml/min according to Cockcroft-Gault formula.
- Systolic blood pressure ≤ 160 mmHg.
- Women of childbearing potential and men must agree to use adequate contraception since signing of the informed consent form until at least 3 months after the last study drug administration. The investigator or a designated associate is requested to advise the subject on how to achieve adequate birth control. Adequate contraception is defined in the study as any medically recommended method (or combination of methods) as per standard of care.
- International normalized ratio (INR) ≤ 1.5 x ULN and partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN unless receiving treatment with therapeutic anticoagulation. Patients being treated with anticoagulant e.g. heparin will be allowed to participate provided no prior evidence of an underlying abnormality in these parameters exists.
Exclusion Criteria:
- Patients who are receiving any other investigational agents.
- Previous assignment to treatment during this study. Subjects permanently withdrawn from study treatment participation will not be allowed to re-enter the study.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition used in the study.
- Prior treatment with regorafenib.
- Previous or concurrent cancer that is distinct in primary site of histology from EOC within the last 5 years EXCEPT for curatively treated cervical cancer in situ, non melanoma skin cancer and superficial bladder tumours [Ta (non invasive tumour), Tis (carcinoma in situ) and T1 (tumour invades lamina propria)].
- Patients with known brain metastases.
- Uncontrolled inter-current illness including, but not limited to, on going or active infection (> Grade 2 NCI CTCAE v 4.00), symptomatic congestive heart failure (≥ New York Heart Association (NYHA) class 2), unstable angina pectoris, new onset angina (begun within the last 3 months), myocardial infarction less than 6 months before, cardiac arrhythmia requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted), pre existing poorly controlled hypertension (systolic blood pressure > 160mmHg or diastolic pressure > 90 mmHg despite optimal medical management), history of abdominal fistula, history of gastrointestinal perforation and signs or symptoms of bowel obstruction.
- Subjects with phaeochromocytoma.
- Other concurrent severe and/or uncontrolled concomitant medical conditions that could cause unacceptable safety risk or compromise compliance with the protocol.
- Patients unable to swallow orally administered medication and patients with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of either study drug (e.g. ulcerative diseases, uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome).
- Patients who have undergone major surgery, open biopsy of significant traumatic injury ≤ 28 days prior to starting study drug.
- Patient with bowel resection within the past 1 year.
- Patients with a past history of bowel perforation and abdominal fistula; patients with a recent history of bowel resection (within the past 12 months) and/or patients with symptoms of radiological evidence of active bowel obstruction.
- Extended field radiotherapy within 4 weeks or limited field radiotherapy within 2 weeks prior to randomization. Patients must have recovered from all therapy related toxicities. The site of previous radiotherapy should have evidence of progressive disease if this is the only site of disease.
- Patients with venous thromboembolism disease or pulmonary embolism within 6 months before start of study medication (except for adequately treated catheter-related venous thrombosis occurring more than one month before the start of study medication).
- Arterial thrombotic event including transient ischaemic attack (TIA), cerebrovascular accident (CVA) and peripheral arterial embolus within the last 6 months before start of study medication.
- Subjects with evidence or history of any bleeding diathesis irrespective of severity.
- Non-healing wound, ulcer or bone fracture.
- Known history of human immunodeficiency virus (HIV) infection.
- Subjects with seizure disorder requiring medication.
- History of organ allograft.
- Renal failure requiring haemo- or peritoneal dialysis.
- Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
- Interstitial lung disease with on-going signs and symptoms at the time of informed consent.
- Systemic anticancer therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy and hormonal therapy during this trial or within 4 weeks (or 6 weeks for nitrosurea, antibodies or mitomycin-C) prior to starting study drug or who have not recovered from side effects of such therapy.
- Pregnant or breast-feeding in females. Women of childbearing potential must have a pregnancy test performed a maximum of 7 days before start of treatment, and a negative result must be documented before start of treatment.
- Inability to attend or comply with treatment of follow-up scheduling.
- Persistent proteinuria > 3.5g/24 hours measured by urine protein-creatinine ratio from a random urine sample
- Any haemorrhage or bleeding event ≥ CTCAE Grade 3 within 4 weeks prior to the start of study medication
- Active hepatitis B or C, or chronic hepatitis B or C requiring treatment with antiviral therapy
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Regorafenib
Patients will receive Regorafenib 120mg once daily, with consideration for dose escalation to 160mg if there are no toxicities
|
Once a day for 21 days in a 28 days cycle
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Investigator assessed progression free survival (PFS)
Tidsram: 30 days after the last dose of regorafenib
|
30 days after the last dose of regorafenib
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Overall survival (OS)
Tidsram: 30 days after the last dose of regorafenib
|
30 days after the last dose of regorafenib
|
|
Overall tumour response rate (ORR) as per Gynecological Cancer Intergroup (GCIG) and RECIST v1.1 criteria
Tidsram: 30 days after the last dose of regorafenib
|
30 days after the last dose of regorafenib
|
|
Treatment Emergent Adverse Events
Tidsram: 30 days after the last dose of regorafenib
|
During the study period, patients will undergo evaluations for safety and drug tolerability.
|
30 days after the last dose of regorafenib
|
Andra resultatmått
Resultatmått |
Tidsram |
---|---|
Health Related Quality of Life (HRQoL)
Tidsram: 30 days after the last dose of regorafenib
|
30 days after the last dose of regorafenib
|
Maximum Plasma Concentration [Cmax]
Tidsram: 30 days after the last dose of regorafenib
|
30 days after the last dose of regorafenib
|
Area Under the Curve (AUC)
Tidsram: 30 days after the last dose of regorafenib
|
30 days after the last dose of regorafenib
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Wen Yee Chay, MBBS, National Cancer Centre, Singapore
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter histologisk typ
- Neoplasmer
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Carcinom
- Neoplasmer, körtel och epitel
- Genitala neoplasmer, hona
- Sjukdomar i det endokrina systemet
- Ovariella sjukdomar
- Adnexala sjukdomar
- Gonadal sjukdomar
- Neoplasmer i endokrina körtel
- Ovariella neoplasmer
- Karcinom, äggstocksepitel
Andra studie-ID-nummer
- NCC OV-01
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Ovariella neoplasmer
-
Ann & Robert H Lurie Children's Hospital of ChicagoOkändCystektomi | Godartade cystor Ovarian | Torsion | Maligna cystor OvarianFörenta staterna
-
Universitair Ziekenhuis BrusselRekrytering
-
Royal Surrey County Hospital NHS Foundation TrustOkändÄggstockscancer | Äggledarcancer | Peritoneal cancer | Ovarial neoplasm | Ovarian Neoplasm EpitelialStorbritannien
-
Assistance Publique - Hôpitaux de ParisAktiv, inte rekryterandeOkomplicerad Tubo Ovarian AbscessFrankrike
-
Universitair Ziekenhuis BrusselRekrytering
-
Royal Surrey County Hospital NHS Foundation TrustRekryteringÄggledarneoplasmer | Äggstockscancer | Äggledarcancer | Peritoneal cancer | Ovarial neoplasm | Ovarian Neoplasm EpitelialStorbritannien
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)AvslutadMetastatisk malign neoplasm | Ooperbar malign neoplasm | Avancerad malign neoplasmFörenta staterna
-
Leiden University Medical CenterUniversity Medical Center Groningen; Erasmus Medical CenterRekryteringBRCA1-mutation | BRCA2-mutation | Homolog rekombinationsbrist | Ovarian Neoplasm EpitelialNederländerna
-
Massachusetts General HospitalRekryteringMalign neoplasm | Benign neoplasmFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeMetastatisk malign neoplasm | Avancerad malign neoplasm | Återkommande malign neoplasm | Refraktär malign neoplasm | Lokalt avancerad malign neoplasmFörenta staterna
Kliniska prövningar på Regorafenib
-
Second Affiliated Hospital of Guangzhou Medical...Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Shenzhen... och andra samarbetspartnersAktiv, inte rekryterandeHepatocellulärt karcinom Ej resektabeltKina
-
Zhongda HospitalSun Yat-sen University; Jiangsu Cancer Institute & Hospital; Zhejiang University och andra samarbetspartnersHar inte rekryterat ännuHepatocellulärt karcinom
-
Spanish Cooperative Group for the Treatment of...BayerAvslutadKolorektala neoplasmer | Metastaserande sjukdomSpanien
-
Rennes University HospitalRekrytering
-
Taipei Veterans General Hospital, TaiwanChang Gung Memorial Hospital; Koo Foundation Sun Yat-Sen Cancer CenterAvslutadMetastaserande kolorektal cancerTaiwan
-
Spanish Cooperative Group for the Treatment of...BayerAvslutadMetastaserande kolorektal cancerSpanien
-
BayerAvslutadNeoplasmFörenta staterna
-
Tianjin Medical University Cancer Institute and...Har inte rekryterat ännuAvancerad/metastaserande kolorektal cancerKina
-
Gustave Roussy, Cancer Campus, Grand ParisBayerRekrytering
-
Institute of Mother and Child, Warsaw, PolandMaria Sklodowska-Curie National Research Institute of OncologyRekryteringOsteosarkom | Ewing Sarcoma of BonePolen